Neurological Surgery Resident Award :Presentation: P13BP, a Calpain-2-Mediated Breakdown Product of PTPN13, Is a Novel Blood Biomarker for Traumatic Brain Injury

Thursday, September 15, 2022

4:30 PM – 4:40 PM East Coast USA Time

Location: JW Grand Ballroom 4

Reference 1: McAllister 2022. Neurobiological consequences of traumatic brain injury. Dialogues in Clinical Neuroscience.
Reference 2: Newcombe et al. 2022. Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain, Volume 145, Issue 6, June 2022, Pages 2064–2076
Reference 3: Khan et al. 2022. Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases. Neurochemical Research volume 47, pages1125–1149

Member Speaker(s)

Tye Patchana, DO

Neurosurgery Resident
Riverside University Health System Medical Center

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Tye Patchana, DO: No financial relationships to disclose

Learning Objectives:

Understand the utility of using novel biomarkers in the treatment of traumatic brain injury.
Describe various biomarkers and understand their uses and limitations in the treatment of traumatic brain injury.
Describe the cascade of events occurring following traumatic brain injury.